AXSM earnings: next report 2026-08-10, real EPS beat/miss history, analyst consensus Buy, P/E -64.24. Updated 2026-07-23.
Axsome Therapeutics (AXSM) Research Hub
Axsome Therapeutics (AXSM) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 220.75 USD (+4.80%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -64.24, market cap 12.27B. This hub links to the full technical, earnings and options research available for AXSM.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 220.75 USD (+4.80%) |
| 52-week range | 199 USD – 255.09 USD |
| Trend regime | Range |
| 14-day RSI | 57 (Bullish) |
| Trailing P/E | -64.24 |
| Market cap | 12.27B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-10 |
Available research for AXSM
Covered Call on AXSM: how it works, illustrative setup around the real 220.75 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on AXSM: how it works, illustrative setup around the real 220.75 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on AXSM: how it works, illustrative setup around the real 220.75 USD price, max profit/loss, breakeven and when to use it. Educational.
AXSM technical analysis: range, last 220.75 USD, RSI 57, 52w range 199 USD–255.09 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is AXSM in?
Axsome Therapeutics (AXSM) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is AXSM in an uptrend or downtrend?
As of 2026-09-11, AXSM is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is AXSM's trailing P/E ratio?
AXSM's trailing P/E is -64.24, with a market cap of 12.27B. See the earnings research page for full valuation detail.
When does AXSM next report earnings?
AXSM is next scheduled to report earnings on 2026-08-10, with a consensus EPS estimate of -0.8938 USD.